Abstract:Motivation: Computational prediction of compound-protein interactions (CPIs) is of great importance for drug design and development, as genome-scale experimental validation of CPIs is not only time-consuming but also prohibitively expensive. With the availability of an increasing number of validated interactions, the performance of computational prediction approaches is severely impended by the lack of reliable negative CPI samples. A systematic method of screening reliable negative sample becomes critical to improving the performance of in silico prediction methods.Results: This article aims at building up a set of highly credible negative samples of CPIs via an in silico screening method. As most existing computational models assume that similar compounds are likely to interact with similar target proteins and achieve remarkable performance, it is rational to identify potential negative samples based on the converse negative proposition that the proteins dissimilar to every known/predicted target of a compound are not much likely to be targeted by the compound and vice versa. We integrated various resources, including chemical structures, chemical expression profiles and side effects of compounds, amino acid sequences, protein-protein interaction network and functional annotations of proteins, into a systematic screening framework. We first tested the screened negative samples on six classical classifiers, and all these classifiers achieved remarkably higher performance on our negative samples than on randomly generated negative samples for both human and Caenorhabditis elegans. We then verified the negative samples on three existing prediction models, including bipartite local model, Gaussian kernel profile and Bayesian matrix factorization, and found that the performances of these models are also significantly improved on the screened negative samples. Moreover, we validated the screened negative samples on a drug bioactivity dataset. Finally, we derived two sets of new interactions by training an support vector machine classifier on the positive interactions annotated in DrugBank and our screened negative interactions. The screened negative samples and the predicted interactions provide the research community with a useful resource for identifying new drug targets and a helpful supplement to the current curated compound-protein databases.

Application of Negative Design to Design a More Desirable Virtual Screening Library.

Scopy: an integrated negative design python library for desirable HTS/VS database design

Advances in Computational Structure-Based Drug Design and Application in Drug Discovery.

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

Negative Image-Based Screening: Rigid Docking Using Cavity Information

Improving Compound-Protein Interaction Prediction by Building Up Highly Credible Negative Samples

Traditional and Machine Learning Approaches in Structure-Based Drug Virtual Screening

Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances

Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design

Research on the application of computer in drug design

A Guide to In Silico Drug Design

Virtual Screening Methods As Tools For Drug Lead Discovery From Large Chemical Libraries

Virtual Screening Methods As Tools for Drug Lead Discovery from Large Chemical Libraries.

The Application of in Silico Drug-Likeness Predictions in Pharmaceutical Research.

Virtual screening web servers: designing chemical probes and drug candidates in the cyberspace

Focused Combinatorial Library Design Based on Structural Diversity, Druglikeness and Binding Affinity Score.

Drug Target Identification with Machine Learning: How to Choose Negative Examples

Recent Trends in Drug Design and Discovery

Automatic Tailoring and Transplanting: A Practical Method That Makes Virtual Screening More Useful.

Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem

Application of Reverse Docking in the Research of Small Molecule Drugs and Traditional Chinese Medicine.